Calamos Advisors LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is and the CUSIP is 40637HAD1. A total of 64 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Calamos Advisors LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$3,879,306
-34.3%
4,580,000
-35.3%
0.02%
-31.0%
Q2 2023$5,900,417
-3.5%
7,079,000
-1.8%
0.03%
-3.3%
Q1 2023$6,116,820
+5.8%
7,210,000
+21.6%
0.03%
+11.1%
Q4 2022$5,780,861
-71.4%
5,930,000
-75.1%
0.03%
-71.0%
Q3 2022$20,236,000
-47.5%
23,808,000
-45.4%
0.09%
-44.0%
Q2 2022$38,575,000
+0.4%
43,634,000
+0.0%
0.17%
+15.3%
Q1 2022$38,410,00043,624,0000.14%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Wellesley Asset Management 128,679,626$110,468,0065.49%
CAMDEN ASSET MANAGEMENT L P /CA 77,223,000$65,160,7672.42%
Penn Mutual Asset Management 1,555,000$1,312,1091.23%
ZAZOVE ASSOCIATES LLC 9,108,000$7,715,0000.80%
DAVIDSON KEMPNER CAPITAL MANAGEMENT LP 50,000,000$42,190,0000.67%
LAFFER TENGLER INVESTMENTS, INC. 2,399$2,032,8230.60%
SHENKMAN CAPITAL MANAGEMENT INC 9,019,000$7,767,6720.58%
LINDEN ADVISORS LP 62,930,000$53,329,4250.55%
SSI INVESTMENT MANAGEMENT LLC 4,577,000$3,862,0740.32%
Sonora Investment Management Group, LLC 4,355,000$3,675,0600.31%
View complete list of HALOZYME THERAPEUTICS INC shareholders